Figure 2From: Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer Comparison of worst rash scores per patient by EIR and CTCAE scales. Back to article page